Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class ...

Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...

Mounjaro will be rolled out gradually as officials said a "difficult decision" had to be made in order to "protect other ...

To help the NHS manage demand, the health organisation's spending watchdog said about 220,000 people could benefit from the ...

Fewer than 10 per cent of patients in England who are eligible for what has been dubbed the “King Kong of weight loss drugs” ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Amylyx (AMLX) announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

The rise of weight loss drugs is not only changing individual lives, but also reshaping large sections of the economy.